ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 184 filers reported holding ARCUS BIOSCIENCES INC in Q2 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,545,451 | +80.8% | 232,794 | +124.1% | 0.02% | +76.9% |
| Q1 2024 | $1,960,876 | -55.5% | 103,860 | -55.0% | 0.01% | -55.2% |
| Q4 2023 | $4,408,662 | +71.9% | 230,820 | +61.5% | 0.03% | +45.0% |
| Q3 2023 | $2,565,055 | -31.0% | 142,900 | -21.9% | 0.02% | -37.5% |
| Q2 2023 | $3,717,216 | -30.6% | 183,024 | -37.7% | 0.03% | -37.3% |
| Q1 2023 | $5,359,093 | +67.9% | 293,810 | +90.4% | 0.05% | +88.9% |
| Q4 2022 | $3,191,731 | -6.6% | 154,339 | +18.2% | 0.03% | -6.9% |
| Q3 2022 | $3,417,000 | -18.6% | 130,628 | -21.1% | 0.03% | -29.3% |
| Q2 2022 | $4,196,000 | +316.3% | 165,588 | +565.0% | 0.04% | +355.6% |
| Q4 2021 | $1,008,000 | +18.4% | 24,900 | +2.0% | 0.01% | 0.0% |
| Q3 2021 | $851,000 | -40.2% | 24,400 | -51.9% | 0.01% | -47.1% |
| Q1 2021 | $1,424,000 | +250.7% | 50,701 | +224.5% | 0.02% | +240.0% |
| Q4 2020 | $406,000 | – | 15,625 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $29,404,284 | 19.15% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,864,970 | 6.40% |
| Octagon Capital Advisors LP | 2,172,000 | $39,617,280 | 5.70% |
| Boxer Capital, LLC | 1,432,200 | $26,123 | 1.28% |
| PFM Health Sciences, LP | 1,559,947 | $28,453,433 | 1.26% |
| SECTORAL ASSET MANAGEMENT INC | 293,646 | $5,356,103 | 1.03% |
| DAFNA Capital Management LLC | 175,217 | $3,195,958 | 0.96% |
| Ikarian Capital, LLC | 230,000 | $4,195,200 | 0.95% |
| Tejara Capital Ltd | 50,000 | $912,000 | 0.47% |
| Capital Impact Advisors, LLC | 20,501 | $373,938 | 0.46% |